NO20084282L - Ny krystallinsk form for (5S)-5-[4-(5-klorpyridin-2-yloksy)piperidin-1-sulfonylmetyl]-5-metylimidazolin-2,4-dion(l) og mellomprodukter derav - Google Patents

Ny krystallinsk form for (5S)-5-[4-(5-klorpyridin-2-yloksy)piperidin-1-sulfonylmetyl]-5-metylimidazolin-2,4-dion(l) og mellomprodukter derav

Info

Publication number
NO20084282L
NO20084282L NO20084282A NO20084282A NO20084282L NO 20084282 L NO20084282 L NO 20084282L NO 20084282 A NO20084282 A NO 20084282A NO 20084282 A NO20084282 A NO 20084282A NO 20084282 L NO20084282 L NO 20084282L
Authority
NO
Norway
Prior art keywords
sulfonylmethyl
yloxy
dione
methylimidazoline
chloropyridin
Prior art date
Application number
NO20084282A
Other languages
English (en)
Norwegian (no)
Inventor
Anders Eriksson
Neil Barnwell
Andrew Wells
Luis-Manuel Vaz
Lars-Erik Briggner
Andrea Cole
Jacob Perkins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38509897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084282(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084282L publication Critical patent/NO20084282L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20084282A 2006-03-16 2008-10-13 Ny krystallinsk form for (5S)-5-[4-(5-klorpyridin-2-yloksy)piperidin-1-sulfonylmetyl]-5-metylimidazolin-2,4-dion(l) og mellomprodukter derav NO20084282L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78297906P 2006-03-16 2006-03-16
PCT/SE2007/000256 WO2007106022A2 (en) 2006-03-16 2007-03-15 A new crystalline form g of (5s) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (i) and intermediates thereof.

Publications (1)

Publication Number Publication Date
NO20084282L true NO20084282L (no) 2008-10-13

Family

ID=38509897

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084282A NO20084282L (no) 2006-03-16 2008-10-13 Ny krystallinsk form for (5S)-5-[4-(5-klorpyridin-2-yloksy)piperidin-1-sulfonylmetyl]-5-metylimidazolin-2,4-dion(l) og mellomprodukter derav

Country Status (16)

Country Link
US (1) US20090221640A1 (es)
EP (1) EP2064202A4 (es)
JP (1) JP2009531313A (es)
KR (1) KR20090008229A (es)
CN (1) CN101448819A (es)
AR (1) AR059913A1 (es)
AU (1) AU2007225477A1 (es)
BR (1) BRPI0709579A2 (es)
CA (1) CA2644345A1 (es)
CL (1) CL2007000680A1 (es)
IL (1) IL193670A0 (es)
MX (1) MX2008011641A (es)
NO (1) NO20084282L (es)
TW (1) TW200800954A (es)
UY (1) UY30214A1 (es)
WO (1) WO2007106022A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN103282346B (zh) * 2011-01-13 2014-11-19 比皮艾思药物研发有限公司 用于制备苯基氨基甲酸酯衍生物的方法
WO2013100568A1 (en) 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
SG11201509022XA (en) 2013-05-02 2015-12-30 Api Corp METHOD FOR PRODUCING α-SUBSTITUTED CYSTEINE OR SALT THEREOF OR INTERMEDIATE FOR SYNTHESIS OF α-SUBSTITUTED CYSTEINE
US20230255943A1 (en) 2020-06-26 2023-08-17 The University Of Birmingham Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172762A (ja) * 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
GB8618559D0 (en) * 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) * 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) * 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
NL9201230A (nl) * 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
TW514634B (en) * 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
BR0208105A (pt) * 2001-03-15 2004-03-09 Astrazeneca Ab Inibidores de metaloproteinase
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2003093260A1 (en) * 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
PL373788A1 (en) * 2002-05-10 2005-09-19 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
EP1550725A4 (en) * 2002-06-05 2010-08-25 Kaneka Corp PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine

Also Published As

Publication number Publication date
WO2007106022A2 (en) 2007-09-20
AR059913A1 (es) 2008-05-07
IL193670A0 (en) 2009-05-04
AU2007225477A1 (en) 2007-09-20
EP2064202A2 (en) 2009-06-03
MX2008011641A (es) 2008-09-22
CL2007000680A1 (es) 2008-02-08
TW200800954A (en) 2008-01-01
WO2007106022A3 (en) 2007-11-01
US20090221640A1 (en) 2009-09-03
CN101448819A (zh) 2009-06-03
CA2644345A1 (en) 2007-09-20
BRPI0709579A2 (pt) 2011-07-19
EP2064202A4 (en) 2011-01-12
JP2009531313A (ja) 2009-09-03
UY30214A1 (es) 2007-10-31
KR20090008229A (ko) 2009-01-21

Similar Documents

Publication Publication Date Title
NO20084282L (no) Ny krystallinsk form for (5S)-5-[4-(5-klorpyridin-2-yloksy)piperidin-1-sulfonylmetyl]-5-metylimidazolin-2,4-dion(l) og mellomprodukter derav
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20090052L (no) Nye forbindelser
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
NO20080010L (no) GPCR-agonister
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20093200L (no) Tiazolidinderivater
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20066055L (no) Pyridinderivater
NO20090628L (no) Pyridizinon derivativater
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20084328L (no) Nye forbindelser
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
WO2008032191A3 (en) Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
NO20071073L (no) Heterocykel-substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
TW200716628A (en) Novel compounds
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
SG170785A1 (en) Benzothiazoles having histamine h3 receptor activity
NO20064522L (no) Novel pharmaceutical compositions
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application